- Home
- INCY vs NBIX Comparison
INCY vs NBIX Comparison
Compare INCY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- NBIX
- Stock Information
- Founded
- INCY 1991
- NBIX 1992
- Country
- INCY United States
- NBIX United States
- Employees
- INCY N/A
- NBIX N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INCY Health Care
- NBIX Health Care
- Exchange
- INCY Nasdaq
- NBIX Nasdaq
- Market Cap
- INCY 17.0B
- NBIX 14.4B
- IPO Year
- INCY 1993
- NBIX 1996
- Fundamental
- Price
- INCY $105.57
- NBIX $149.46
- Analyst Decision
- INCY Buy
- NBIX Strong Buy
- Analyst Count
- INCY 19
- NBIX 18
- Target Price
- INCY $89.19
- NBIX $172.06
- AVG Volume (30 Days)
- INCY 2.8M
- NBIX 1.1M
- Earning Date
- INCY 10-28-2025
- NBIX 10-28-2025
- Dividend Yield
- INCY N/A
- NBIX N/A
- EPS Growth
- INCY 3878.02
- NBIX 12.44
- EPS
- INCY 5.90
- NBIX 4.19
- Revenue
- INCY $4,813,105,000.00
- NBIX $2,682,700,000.00
- Revenue This Year
- INCY $19.33
- NBIX $23.68
- Revenue Next Year
- INCY $10.47
- NBIX $18.02
- P/E Ratio
- INCY $17.95
- NBIX $35.79
- Revenue Growth
- INCY 18.09
- NBIX 19.61
- 52 Week Low
- INCY $53.56
- NBIX $84.23
- 52 Week High
- INCY $108.81
- NBIX $157.67
- Technical
- Relative Strength Index (RSI)
- INCY 80.92
- NBIX 58.02
- Support Level
- INCY $91.16
- NBIX $133.62
- Resistance Level
- INCY $106.47
- NBIX $157.67
- Average True Range (ATR)
- INCY 4.31
- NBIX 5.06
- MACD
- INCY 1.48
- NBIX 0.91
- Stochastic Oscillator
- INCY 88.14
- NBIX 65.74
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.